BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30261753)

  • 1. Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1.
    Su JC; Chang CH; Wu SH; Shiau CW
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1248-1255. PubMed ID: 30261753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
    Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
    Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1.
    Gupta SC; Phromnoi K; Aggarwal BB
    Biochem Pharmacol; 2013 Apr; 85(7):898-912. PubMed ID: 23279849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase.
    Kim C; Cho SK; Kapoor S; Kumar A; Vali S; Abbasi T; Kim SH; Sethi G; Ahn KS
    Mol Carcinog; 2014 Oct; 53(10):793-806. PubMed ID: 23765383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.
    Chen KF; Tai WT; Hsu CY; Huang JW; Liu CY; Chen PJ; Kim I; Shiau CW
    Eur J Med Chem; 2012 Sep; 55():220-7. PubMed ID: 22871485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
    Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase.
    Jin Y; Yoon YJ; Jeon YJ; Choi J; Lee YJ; Lee J; Choi S; Nash O; Han DC; Kwon BM
    Biochem Pharmacol; 2017 Oct; 142():46-57. PubMed ID: 28666623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
    Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
    Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
    Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
    Sajith AM; Abdul Khader KK; Joshi N; Reddy MN; Syed Ali Padusha M; Nagaswarupa HP; Nibin Joy M; Bodke YD; Karuvalam RP; Banerjee R; Muralidharan A; Rajendra P
    Eur J Med Chem; 2015 Jan; 89():21-31. PubMed ID: 25462222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
    Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway.
    Xu L; Shi L; Qiu S; Chen S; Lin M; Xiang Y; Zhao C; Zhu J; Shen L; Zuo Z
    Drug Des Devel Ther; 2019; 13():3369-3381. PubMed ID: 31576111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.